Clinical Study

The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients

Table 1

Characteristics of the control group ( ) and HIV-infected patients ( ) at baseline and at follow-up by treatment group.

HIV-infected patients
CharacteristicsControl groupABC-3TC ( )TDF-FTC ( )
BaselineFollowupBaselineFollowup

Gender, male (%)135 (67)24 (68)NA20 (62)NA
Age, years39.1 (0.4)38.9 (0.6)NA38.3 (0.6)NA
BMI, kg/m226.2 (0.2)23.31 (0.2)23.52 (0.4)23.21 (0.2)23.82 (0.3)
Systolic blood pressure, mm Hg119.14 (1.7)118.04 (1.4)120.46 (1.5)118.45 (1.5)121.01 (1.5)
Diastolic blood pressure, mm Hg77.36 (1.2)75.96 (1.1)78.35 (1.9)76.26 (1.4)78.01 (0.97)
Smoking, n (%)90 (39.7)a23 (66)21 (62)20 (62)19 (59)
Total WBC count, cells x 109/LNA4.27 (1.6)4.73 (2.1)4.50 (1.9)4.83 (2.0)
CD4+ T cell count, cells/μLNA458.97 (20.0)b526.33 (24.8)469.87 (20.2)b520.25 (26.8)
Total cholesterol, mmol/L5.02 (0.3)5.06 (0.1)b4.90 (0.1)4.99 (0.1)b4.80 (0.1)
HDL cholesterol, mmol/L1.47 (0.1)a1.17 (0.04)1.19 (0.04)1.18 (0.04)1.19 (0.03)
LDL cholesterol, mmol/L2.78 (0.3)2.82 (0.1)b2.68 (0.1)2.88 (0.1)b2.58 (0.1)
Triglycerides, mmol/L1.1 (0.3)2.50 (0.2)2.53 (0.2)2.49 (0.2)2.59 (0.2)
Glucose, mmol/L4.91 (0.4)5.42 (0.1)5.40 (0.2)5.42 (0.2)5.35 (0.1)
CRP, mg/L0.83 (0.1)a4.67 (3.4)4.81 (3.9)4.85 (3.2)4.76 (4.2)
MCP-1, pg/mL427.9 (149.7)a830.8 (193.3)b555.1 (96.2)846.4 (198.1)826.3 (113.9)
sCD40L, ng/mL2.03 (0.2)1.64 (0.4)1.56 (0.3)1.60 (0.5)1.71 (0.7)
tPA, ng/mL5.63 (0.5)a9.71 (0.86)b6.60 (0.64)9.45 (0.79)b6.10 (0.64)
IL-6, pg/mL3.29 (0.8)a7.19 (1.3)b6.19 (1.3)7.11 (1.5)b6.30 (1.1)
IL-8, pg/mL14.88 (6.1)36.38 (5.2)32.92 (8.1)36.99 (7.3)34.01 (7.9)
P-Selectin, pg/mL185.23 (50.4)205.19 (88.8)199.05 (70.9)211.11 (79.8)200.35 (72.6)

Data are the mean (SEM) unless otherwise indicated. a with respect to baseline values of all HIV-infected patients; b with respect to follow-up values. BMI, body-mass index; NA, not applicable; WBC: white blood cells.